Browse > Article
http://dx.doi.org/10.3345/cep.2021.00696

Updates on the coronavirus disease 2019 vaccine and consideration in children  

Kang, Hyun Mi (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Choi, Eun Hwa (Department of Pediatrics, Seoul National University College of Medicine)
Kim, Yae-Jean (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.64, no.7, 2021 , pp. 328-338 More about this Journal
Abstract
Humanity has been suffering from the global severe acute respiratory syndrome coronavirus 2 pandemic that began late in 2019. In 2020, for the first time in history, new vaccine platforms-including mRNA vaccines and viral vector-based DNA vaccines-have been given emergency use authorization, leading to mass vaccinations. The purpose of this article is to review the currently most widely used coronavirus disease 2019 vaccines, investigate their immunogenicity and efficacy data, and analyze the vaccine safety profiles that have been published, to date.
Keywords
COVID-19; Immunogenicity; Safety; SARS-CoV-2; Vaccines;
Citations & Related Records
연도 인용수 순위
  • Reference
1 World Health Organization. Status of COVID-19 vaccines within WHO EUL/PQ evaluation process [Internet]. Geneva (Switzerland): World Health Organization; 2021 [cited 2021 Mar 12]. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_10March2021.pdf.
2 Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516-27.   DOI
3 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.   DOI
4 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092-101.   DOI
5 Ostergaard SD, Schmidt M, Horvath-Puho E, Thomsen RW, Sorensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet 2021;397:1441-3.   DOI
6 Centers for Disease Control and Prevention. J&J/Janssen update [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2021 [cited 2021 Apr 27]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html.
7 Weber DJ, Rutala WA, Fischer WA, Kanamori H, Sickbert-Bennett EE. Emerging infectious diseases: focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9). Am J Infect Control 2016;44(5 Suppl):e91-100.
8 Park Y, Huh IS, Lee J, Kang CR, Cho SI, Ham HJ, et al. Application of testing-tracing-treatment strategy in response to the COVID-19 outbreak in Seoul, Korea. J Korean Med Sci 2020;35:e396.   DOI
9 Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74.   DOI
10 Afrough S, Rhodes S, Evans T, White R, Benest J. Immunologic dose-response to adenovirus-vectored vaccines in animals and humans: a systematic review of dose-response studies of replication incompetent adenoviral vaccine vectors when given via an intramuscular or subcutaneous route. Vaccines (Basel) 2020;8:131.   DOI
11 Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020;20:689-96.   DOI
12 Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a Trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021;384:1824-35.   DOI
13 U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee. COVID-19 vaccine Ad26.COV2.S. Sponsor Briefing Document [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2021 [cited 2021 Feb 21]. Available from: https://www.fda.gov/media/146219/download.
14 Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124-30.   DOI
15 Mahase E. AstraZeneca vaccine: blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. BMJ 2021;373:n931.   DOI
16 Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med 2020;383:1544-55.   DOI
17 Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021;384:2187-201.   DOI
18 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15.   DOI
19 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16.   DOI
20 Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021;397:881-91.   DOI
21 Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A 2004;101:6146-51.   DOI
22 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92.e6.   DOI
23 Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci 2020;257:118056.   DOI
24 Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020;9:382-5.   DOI
25 Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439-50.   DOI
26 Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78.   DOI
27 Peak CM, Childs LM, Grad YH, Buckee CO. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proc Natl Acad Sci U S A 2017;114:4023-8.   DOI
28 Haber MJ, Shay DK, Davis XM, Patel R, Jin X, Weintraub E, et al. Effectiveness of interventions to reduce contact rates during a simulated influenza pandemic. Emerg Infect Dis 2007;13:581-9.   DOI
29 Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020;1866:165878.   DOI
30 Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology 2018;153:1-9.   DOI
31 Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021;21:73-82.   DOI
32 Pichichero ME. Understanding messenger RNA and other SARS-CoV-2 vaccines [Internet]. Parsippany (NJ): Frontline Medical Communications Inc.; 2020 [cited 2021 Mar 12]. Available from: https://www.mdedge.com/hematology-oncology/article/233491/coronavirus-updates/understanding-messenger-rna-and-other-sars.
33 European Medicines Agency. COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine's benefits currently still outweigh risks - Update [Internet]. Amsterdam (Netherlands): European Medicines Agency; 2021 [cited 2021 Apr 1]. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-pracinvestigating-cases-thromboembolic-events-vaccines-benefits.
34 Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med 2021;384:1964-5.   DOI
35 European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets [Internet]. Amsterdam (Netherlands): European Medicines Agency; 2021 [cited 2021 Mar 20]. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possiblelink-very-rare-cases-unusual-blood-clots-low-blood.
36 Korea Disease Control and Prevention Agency. Recommencement of the AstraZeneca vaccine that was placed on hold, starting April 12 [Internet]. Cheongju (Korea): Korea Disease Control and Prevention Agency; 2021 [cited 2021 Apr 27]. Available from: http://www.kdca.go.kr/gallery.es?mid=a20503030300&bid=0004&b_list=9&act=view&list_no=145062&nPage=1&vlist_no_npage=1&keyField=&keyWord=&orderby=.
37 Centers for Disease Control and Prevention. 2019-20 Season's pediatric flu deaths tie high mark set during 2017-18 season [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2021 [cited 2021 Mar 4]. Available from: https://www.cdc.gov/flu/spotlights/2019-2020/2019-20-pediatric-flu-deaths.htm#:~:text=LinkedIn-,2019%2D20%20Season's%20Pediatric%20Flu%20Deaths%20Tie%20High,Set%20During%202017%2D18%20Season&text=August%2021%2C%202020%20%E2%80%93%20CDC%20today,for%20last%20season%20to%20188.
38 Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020;586:567-71.   DOI
39 Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. Hum Vaccin Immunother 2016;12:2064-74.   DOI
40 World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. Geneva (Switzerland): World Health Organization; 2021 [cited 2021 Mar 12]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
41 Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr 2020;63:125-32.   DOI
42 Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther 2014;22:668-74.   DOI
43 U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2021 [cited 2021 Feb 21]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizerbiontech-covid-19-vaccine-emergency-use.
44 Johnson & Johnson. Johnson & Johnson expands phase 2a clinical trial of COVID-19 vaccine candidate to include adolescents [Internet]. New Brunswick (NJ): Johnson & Johnson; 2021 [cited 2021 Apr 27]. Available from: https://www.jnj.com/johnson-johnson-expands-phase2a-clinical-trial-of-covid-19-vaccine-candidate-to-include-adolescents.
45 Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-5.   DOI
46 Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. Detection of Covid-19 in children in early January 2020 in Wuhan, China. N Engl J Med 2020;382:1370-1.   DOI
47 Pfizer. Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents [Internet]. New York: Pfizer; 2021 [cited 2021 Mar 31]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positivetopline-results-pivotal.
48 Moderna. Kidcove Study Trial ID: NCT04796896 [Internet]. Cambridge (MA): Moderna; 2021 [cited 2021 Mar 31]. Available from: https://connect.trialscope.com/studies/0e8fc8e6-5782-46fd-8b03-0994a5ad8b41.
49 ModernaTX Inc. A study to evaluate safety and effectiveness of mRNA-1273 vaccine in healthy children between 6 months of age and less than 12 years of age [Internet]. Cambridge (MA): Moderna; 2021 [cited 2021 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04796896.
50 National Institute for Health Research. First children's COVID-19 vaccine trial open [Internet]. London: National Institute for Health Research; 2021 [cited 2021 Mar 31]. Available from: https://www.nihr.ac.uk/news/first-childrens-covid-19-vaccine-trial-open/26870.
51 United Nations. Population Division (2019). World Population Prospects 2019, custom data acquired via website [Internet]. New York: United Nations; 2021 [cited 2021 Apr 14]. Available from: https://population.un.org/wpp/DataQuery/.
52 Han MS, Choi EH, Chang SH, Jin BL, Lee EJ, Kim BN, et al. Clinical characteristics and viral RNA detection in children with coronavirus disease 2019 in the Republic of Korea. JAMA Pediatr 2021;175:73-80.   DOI
53 Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis 2020;71:1547-51.   DOI
54 American Academy of Pediatrics. Children and COVID-19: state-level data report [Internet]. Itasca (IL): American Academy of Pediatrics; 2021 [cited 2021 Apr 2]. Available from: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/.
55 Klass P, Ratner AJ. Vaccinating Children against Covid-19 - The Lessons of Measles. N Engl J Med 2021;384:589-91.   DOI
56 Anderson EJ, Campbell JD, Creech CB, Frenck R, Kamidani S, Munoz FM, et al. Warp Speed for COVID-19 Vaccines: Why are Children Stuck in Neutral? Clin Infect Dis 2020 Sep 18;ciaa1425. https://doi.org/10.1093/cid/ciaa1425. Epub.   DOI
57 Wong BLH, Ramsay ME, Ladhani SN. Should children be vaccinated against COVID-19 now? Arch Dis Child 2021 Jan 5:archdischild-2020-321225. https://doi.org/10.1136/archdischild-2020-321225. Epub.   DOI
58 AAP News and Journals. Children make up nearly 21% of new COVID-19 cases [Internet]. Itasca (IL): American Academy of Pediatrics; 2021 [cited 2021 May 28]. Available from: https://www.aappublications.org/news/2021/04/19/pediatric-covid-cases-041921.
59 Goodman B. Children likely the 'leading edge' in spread of COVID-19 variants [Internet]. New York: Medscape LLC; 2021 [cited 2021 Mar 31]. Available from: https://www.medscape.com/viewarticle/948584.
60 Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020;41:1141-9.   DOI
61 Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020;383:1920-31.   DOI